KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
bevacizumab Sensitive: C3 – Early Trials
|
bevacizumab Sensitive: C3 – Early Trials
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
cobimetinib + HM95573 Sensitive: C3 – Early Trials
|
cobimetinib + HM95573 Sensitive: C3 – Early Trials
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
AZD1775 Sensitive: C3 – Early Trials
|
AZD1775 Sensitive: C3 – Early Trials
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
selumetinib + RTB101 Sensitive: D – Preclinical
|
selumetinib + RTB101 Sensitive: D – Preclinical
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
RTB101 Sensitive: D – Preclinical
|
RTB101 Sensitive: D – Preclinical
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|